Guidance

Influenza post exposure prophylaxis and treatment: PGD templates

Patient group direction (PGD) templates for post exposure prophylaxis and treatment of flu for adult residents and staff of care homes.

From:
UK Health Security Agency
Published
12 January 2016
Last updated
16 August 2022 — See all updates

Documents

Oseltamivir 75mg and 30mg capsules for post exposure prophylaxis of influenza: PGD template

Ref: UKHSA publications gateway number GOV-12936

MS Word Document, 169 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Zanamivir inhalation powder for post exposure prophylaxis of influenza: PGD template

Ref: UKHSA publications gateway number GOV-12936

MS Word Document, 160 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Oseltamivir 75mg and 30mg capsules for the treatment of influenza: PGD template

Ref: UKHSA publications gateway number GOV-12936

MS Word Document, 173 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Zanamivir inhalation powder for the treatment of influenza: PGD template

Ref: UKHSA publications gateway number GOV-12936

MS Word Document, 155 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These patient group direction (PGD) templates support the supply of:

  • oseltamivir 75mg and 30mg capsules for post exposure prophylaxis (PEP) of influenza
  • zanamivir inhalation powder for PEP of influenza
  • oseltamivir 75mg and 30mg capsules for the treatment of influenza
  • zanamivir inhalation powder for the treatment of influenza

They all apply to adult residents/users and staff of care facilities (with or without nursing) and are valid from 8 August 2022 until 7 August 2025.

The PGD templates require further authorisation by a clinical governance or patient safety lead, who has designated responsibility for signing PGDs, so the documents meet legal requirements for a PGD. The PGDs are not legal or valid without this local, formal authorisation.

Adoption and governance of the use of these PGDs is the responsibility of the authorising commissioning body and providers.

Provider organisations and health professionals should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body.

Updates to this page

Published 12 January 2016
Last updated 16 August 2022 + show all updates

  1. Updated patient group direction (PGD) templates with latest versions.

  2. Updated 'Oseltamivir' patient group direction (PGD) templates.

  3. Updated Zanamivir powder treatments for influenza guidance.

  4. Updated patient group direction (PGD) templates with latest versions.

  5. First published.

Sign up for emails or print this page

Related content